购物车
- 全部删除
- 您的购物车当前为空
Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) 是一种选择性的,ATP 竞争性和具有口服活性的JAK2抑制剂,对于JAK2和JAK2V617F 激酶的IC50均为 3 nM。它可诱导癌细胞凋亡,可研究骨髓增生性疾病。
Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) 是一种选择性的,ATP 竞争性和具有口服活性的JAK2抑制剂,对于JAK2和JAK2V617F 激酶的IC50均为 3 nM。它可诱导癌细胞凋亡,可研究骨髓增生性疾病。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 197 | 现货 | |
5 mg | ¥ 413 | 现货 | |
10 mg | ¥ 578 | 现货 | |
25 mg | ¥ 783 | 现货 | |
50 mg | ¥ 987 | 现货 | |
100 mg | ¥ 1,230 | 期货 | |
200 mg | ¥ 1,970 | 期货 | |
1 mL x 10 mM (in DMSO) | ¥ 638 | 现货 |
产品描述 | Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor. |
靶点活性 | RET:48 nM, JAK2 (V617F):3 nM, JAK2:3 nM, FLT3:15 nM |
别名 | TG-101348 hydrochloride hydrate, SAR 302503 hydrochloride hydrate |
分子量 | 615.61 |
分子式 | C27H40Cl2N6O4S |
CAS No. | 1374744-69-0 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 120 mg/mL (194.92 mM), Sonication is recommended. H2O: 97 mg/mL (157.56 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.